Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
BBI Solutions
BBI Solutions
Activities:
Ingredients
Analysis
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Ingredients
BBI Solutions completes reagent manufacturer acquisition
BioTeZ is a manufacturer of reagents and finished tests for the in-vitro diagnostics (IVD) market
Finance
BBI creates new jobs to support next phase in COVID-19 home test development
The lateral flow antibody test that can be used by people in their homes to determine if they have an antibody response to COVID-19
Research & Development
BBI Solutions partners to distribute COVID-19 antigens in China
The Native Antigen Company has agreed distribution rights with BBI to provide coronavirus reagents in China
Ingredients
BBI Solutions expands infectious disease reagent suite
BBI Solutions has demonstrated internal antibody development capabilities and has also expanded its infectious disease reagent suite
BBI Solutions increases capacity for transferrin production
BBI Solutions (BBI) has invested in its facilities and resources to increase the capacity of cell culture native human transferrin production by up to 40%
Subscribe now